1. Home
  2. GBIO vs HYFM Comparison

GBIO vs HYFM Comparison

Compare GBIO & HYFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • HYFM
  • Stock Information
  • Founded
  • GBIO 2016
  • HYFM 1977
  • Country
  • GBIO United States
  • HYFM United States
  • Employees
  • GBIO N/A
  • HYFM N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • HYFM Industrial Machinery/Components
  • Sector
  • GBIO Health Care
  • HYFM Industrials
  • Exchange
  • GBIO Nasdaq
  • HYFM Nasdaq
  • Market Cap
  • GBIO 23.2M
  • HYFM 22.8M
  • IPO Year
  • GBIO 2020
  • HYFM 2020
  • Fundamental
  • Price
  • GBIO $0.39
  • HYFM $2.31
  • Analyst Decision
  • GBIO Strong Buy
  • HYFM Hold
  • Analyst Count
  • GBIO 4
  • HYFM 2
  • Target Price
  • GBIO $7.33
  • HYFM $7.00
  • AVG Volume (30 Days)
  • GBIO 559.5K
  • HYFM 873.7K
  • Earning Date
  • GBIO 05-12-2025
  • HYFM 05-13-2025
  • Dividend Yield
  • GBIO N/A
  • HYFM N/A
  • EPS Growth
  • GBIO N/A
  • HYFM N/A
  • EPS
  • GBIO N/A
  • HYFM N/A
  • Revenue
  • GBIO $19,892,000.00
  • HYFM $190,288,000.00
  • Revenue This Year
  • GBIO N/A
  • HYFM $5.45
  • Revenue Next Year
  • GBIO $10.90
  • HYFM $5.33
  • P/E Ratio
  • GBIO N/A
  • HYFM N/A
  • Revenue Growth
  • GBIO 236.92
  • HYFM N/A
  • 52 Week Low
  • GBIO $0.32
  • HYFM $1.50
  • 52 Week High
  • GBIO $4.34
  • HYFM $10.30
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 43.58
  • HYFM 42.36
  • Support Level
  • GBIO $0.34
  • HYFM $1.51
  • Resistance Level
  • GBIO $0.40
  • HYFM $3.10
  • Average True Range (ATR)
  • GBIO 0.05
  • HYFM 0.31
  • MACD
  • GBIO 0.01
  • HYFM 0.17
  • Stochastic Oscillator
  • GBIO 61.29
  • HYFM 50.62

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About HYFM Hydrofarm Holdings Group Inc.

Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.

Share on Social Networks: